Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021146160 - PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING PEDIATRIC HEREDITARY ANGIOEDEMA ATTACK

Publication Number WO/2021/146160
Publication Date 22.07.2021
International Application No. PCT/US2021/013035
International Filing Date 12.01.2021
IPC
A61P 7/10 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
10Antioedematous agents; Diuretics
C07K 16/40 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40against enzymes
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED [JP]/[JP]
Inventors
  • NURSE, Christina
  • HAO, Xinming
Agents
  • WITTE-GARCIA, Chelsea, E.
  • ALAM, Saad
  • ATTISHA, Michael, J.
  • AMUNDSEN, Eric, L.
  • MAGOVCEVIC-LIEBISCH, Ivana
Priority Data
62/960,33313.01.2020US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING PEDIATRIC HEREDITARY ANGIOEDEMA ATTACK
(FR) INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE ET LEURS UTILISATIONS POUR TRAITER UNE CRISE D'ANGIO-ŒDÈME HÉRÉDITAIRE PÉDIATRIQUE
Abstract
(EN)
Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two weeks or at about 150 mg every four weeks.
(FR)
L'invention concerne des méthodes de traitement et de prévention d'une crise d'angio-œdème héréditaire chez des sous-populations pédiatriques à l'aide d'anticorps se liant à la kallicréine plasmatique active, administrés selon des schémas thérapeutiques spécifiques, par exemple, à environ 150 mg toutes les deux semaines ou à environ 150 mg toutes les quatre semaines.
Latest bibliographic data on file with the International Bureau